Estudio de Dosis Ascendente Única de la Inyección HEC-151
Un ensayo clínico de Fase I que evalúa la seguridad, la tolerabilidad, las características farmacocinéticas/farmacodinámicas de una dosis única de la inyección HEC-151 en participantes chinos sanos en un estudio monocéntrico, aleatorizado, con control de placebo (simple ciego) y control positivo (abierto)
Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Chengyong Tang, Doctor
- Número de teléfono: +8618983286980
- Correo electrónico: 17235387@qq.com
Ubicaciones de estudio
-
-
Bishan
-
Chongqing, Bishan, Porcelana, 402760
- Reclutamiento
- No. 9, Shuangxing Avenue,, Bishan
-
Contacto:
- Chengyong Tang, Doctor
- Número de teléfono: 8618983286980
- Correo electrónico: 17235387@qq.com
-
-
Chongqing Municipality
-
Bishan, Chongqing Municipality, Porcelana, 402760
- Aún no reclutando
- No. 9, Shuangxing Avenue,
-
Contacto:
- Chengyong Tang, Doctor
- Número de teléfono: +8618983286980
- Correo electrónico: 17235387@qq.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures;
- When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible;
- During the screening process, male subjects with a body weight of ≥ 50 kg and a body mass index (BMI) of ≥ 19.0 and ≤ 24.0 kg/m2 are included;
- Normal glucose tolerance [3.9 mmol/L < fasting blood glucose (FPG) < 6.1 mmol/L, and 2-hour post-glucose tolerance test (OGTT) blood glucose after sugar intake < 7.8 mmol/L];
- Normal results of insulin release test (IRT), or abnormal results but judged by the researcher to have no clinical significance;
- Glycated hemoglobin (HbA1c) < 5.7%;
- During the study period, there are no plans for reproduction, sperm collection, or sperm donation, and are willing to take effective contraceptive measures throughout the study period until 3 months after the administration of the investigational drug.
Exclusion Criteria:
- Participants with abnormal medical histories or surgical histories judged clinically significant by the researchers, or currently suffering from any diseases in the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, etc. that are judged clinically significant by the researchers, or any other diseases or physiological conditions that can significantly affect the absorption, distribution, metabolism or excretion of the drugs;
- Participants who have a known severe allergic history or are allergic to the test drugs and any of their components;
- Participants who had severe trauma or undergone surgery within 90 days before the screening, or plan to undergo major surgery during the study;
- Participants who have a history of hypoglycemia or hyperglycemia within 90 days before the screening, or have a family history of diabetes (first-degree direct relatives);
- Participants who have donated blood or suffered significant blood loss (≥ 400 mL) within 90 days before the screening, or plan to donate blood during the study;
- Participants who have acute diseases or concurrent medication use from the signing of the informed consent form to the first administration of the drug;
- Participants whose vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray examination, etc. results are abnormal and judged by the researchers to have clinical significance;
- Participants whose test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), combined human immunodeficiency virus antigen antibody (HIV), or syphilis spirochete antibody (TP) are positive;
- Participants who have a history of drug abuse or drug use, or whose urine drug screening is positive before the screening;
- Participants who have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, health supplements (except for regular supplementary vitamins and calcium) within 30 days before the screening;
- Participants who have participated in any clinical research of drugs or devices (defined as receiving the test drugs or devices) within 90 days before the screening;
- Participants who have received any vaccine within 30 days before the screening, or plan to receive any type of vaccine during the study;
- Participants who smoke more than 5 cigarettes per day within 90 days before the screening, or cannot comply with the smoking prohibition rule during the study;
- Participants who frequently drink alcohol, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or have a positive alcohol breath test; or who cannot comply with the alcohol prohibition rule during the study;
- Participants who consume excessive tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 mL) or food (such as chocolate) every day within 90 days before the screening, or during the study;
- Participants who have used special diets (including dragon fruit, mango, pomelo, etc.) and/or xanthine diet (salmon, sardines, liver, kidney, etc.) or have other factors affecting drug absorption, distribution, metabolism, and excretion before the signing of the informed consent form to the use of the test drugs, or who cannot comply with the prohibition of eating during the study;
- Participants who have had significant changes in diet or exercise habits within 90 days before the screening, or have engaged in intense exercise before the signing of the informed consent form to the use of the test drugs, or cannot stop during the study;
- Participants who have difficulty in venous blood collection, or cannot tolerate venipuncture, or have a history of fainting or hematemesis;
- Participants who, in the researcher's opinion, have other factors that are not suitable for participating in this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: HEC-151 Injection
The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
|
Comparador activo: Insulin Degludec
The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
|
Comparador de placebos: Placebo
The participants received an abdominal subcutaneous Injection of placebo in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse event
Periodo de tiempo: From Day1 to Day36
|
Frequency, type and severity of adverse events/serious adverse events. |
From Day1 to Day36
|
|
Electrocardiogram parameter(Heart rate)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the heart rate of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(PR interval)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the PR interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(QTcF interval)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the QTcF interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(QRS interval)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the QRS interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Body temperature)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the body temperature of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Blood pressure)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the blood pressure of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Pulse)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the pulse of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Respiration)
Periodo de tiempo: From Day1 to Day36
|
Evaluation the respiration of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cmax
Periodo de tiempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
AUC0-t
Periodo de tiempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
Tmax
Periodo de tiempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
T1/2
Periodo de tiempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
CL/F
Periodo de tiempo: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
GIRmax
Periodo de tiempo: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
tGIRmax
Periodo de tiempo: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
AUCGIR
Periodo de tiempo: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
ADA(Anti-Drug Antibody)
Periodo de tiempo: From Day1 to Day36
|
Evaluate the Immunogenic characteristics of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- HEC-151-DM-101
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .